Non Squamous Non Small Cell Lung Cancer
2 competing products in clinical development for Non Squamous Non Small Cell Lung Cancer.
Pipeline by Phase
Phase 32
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| CT-P51 + EU-approved Keytruda | Celltrion | Phase 3 | Recruiting | 47 |
| Tivantinib + Placebo + Erlotinib | Daiichi Sankyo | Phase 3 | Terminated | 32 |